ArticleOphthalmology and therapy2026
Ocular Surface Outcomes with Different 0.05% Atropine Dosing Frequencies in Children with Myopia: A Secondary Analysis of a Randomized Trial.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionThis study aimed to compare the effects of three dosing frequencies of 0.05% atropine on the ocular surface in children with myopia.
methodsIn this sub-analysis of a randomized controlled trial, children with myopia (aged 6-14 years) were randomized to 0.05% atropine once daily (Qd), twice weekly (Biw), or once weekly (Qw). Objective parameters, including noninvasive tear breakup time (NIBUT), tear meniscus height (TMH), lipid layer thickness (LLT), incomplete blink rate (IBR), and bulbar conjunctival hyperemia index (BCHI), were assessed at baseline, 2 weeks, and 12 months. Subjective symptoms were evaluated using the Ocular Surface Disease Index (OSDI).
resultsAmong 130 children (260 eyes) completing objective assessments (Qd: n = 43; Biw: n = 49; Qw: n = 38), a representative subset of 78 completed the OSDI questionnaire. Dosing frequency had no differential effect on any outcome (time-by-group interaction: all P > 0.05). Across all groups, first and average NIBUT increased significantly from baseline through 12 months (P < 0.001), with a shift toward less severe dry eye grades (P < 0.001). IBR decreased, indicating improved blink quality (P < 0.001) and BCHI decreased by 12 months (P = 0.001). LLT increased transiently at 2 weeks (P = 0.003), while TMH remained stable (P = 0.712). OSDI scores remained stable, with no significant differences among regimens (P = 0.193).
conclusionsDuring the 12-month follow-up period, ocular surface parameters and subjective symptoms remained comparable among the three 0.05% atropine dosing regimens, with no evidence of clinically significant deterioration.
trial registrationChiCTR2100043506.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.